Health Catalyst CEO’s March 10 “Sell‑to‑Cover” Move: $1.85 Share Sale Leaves Ownership Intact Amid Slumping Stock

Insider Selling Amid a Slumping Stock

Health Catalyst’s CEO, Albert Benjamin, has sold 70,455 shares on March 10, 2026 – a “sell‑to‑cover” transaction to meet tax withholding on restricted units, not an arbitrary divestiture. The shares were sold at $1.85, just above the market close of $1.79, and the sale does not change Benjamin’s net ownership, which remains at 1,457,978 shares. The move follows a pattern of routine sell‑to‑cover activity that has characterized Benjamin’s recent filings: a 4,966‑share sale on March 2, a 13,304‑share sale on February 26, and a 930,000‑share purchase earlier in February that was partially offset by a 38,833‑share purchase on the same day. These transactions are typical of a CEO with a significant restricted‑unit balance, and the overall trend shows a slight net decrease in holdings over the past month.

What Investors Should Take Away

From an investment standpoint, the March 10 sale is largely neutral. The stock has been in a steep downtrend – down 10 % in the month, 59 % YTD, and trading near its 52‑week low of $1.56 – and the company’s fundamentals remain weak, with a negative P/E of –1.12 and continued operating losses. Benjamin’s sell‑to‑cover activity does not signal a loss of confidence; instead, it reflects the mechanics of an incentive plan. However, the volume of insider sales in February (over 140,000 shares sold by Benjamin, Landry, and Alger) may raise a flag for value‑oriented investors, suggesting that insiders are comfortable with the current valuation and may be taking profits or managing tax exposure. The broader insider landscape also shows a mix of purchases and sales, with a few executives buying significant stakes in December 2025, hinting that some insiders still see upside potential despite the stock’s recent slide.

Benjamin’s Historical Trading Profile

Albert Benjamin’s trading history portrays a cautious yet active approach. He has consistently used sell‑to‑cover transactions to satisfy tax obligations on vested RSUs, with the most recent sale in March matching a similar pattern in February. Over the past year, Benjamin’s net holdings have fluctuated modestly, with occasional large purchases (e.g., the 467,000‑share buy in September 2025) that suggest confidence in the company’s long‑term trajectory. His trading volume is relatively low compared to other executives, which may reflect a preference to retain a sizable position and avoid market impact. The timing of his trades—often at market close or shortly thereafter—indicates an emphasis on minimizing trading costs and avoiding the appearance of market timing.

Implications for Health Catalyst’s Future

The current insider activity, while not alarming, must be viewed against Health Catalyst’s broader financial picture. The company has filed a new S‑8 to register over four million shares, signaling ongoing capital‑raising ambitions, while its 8‑K reveals modest revenue decline but improved adjusted EBITDA. Investors should watch for future insider purchases that may signal a shift in sentiment, especially if the stock recovers from its current low. In the meantime, Benjamin’s routine sell‑to‑cover transactions suggest that the CEO is primarily focused on meeting regulatory and tax requirements rather than signaling a strategic pivot. For those weighing a position in Health Catalyst, the insider pattern underscores the importance of assessing both the company’s operational metrics and the timing of insider trades to gauge potential upside or downside risks.